Logo image of CADL

CANDEL THERAPEUTICS INC (CADL) Stock Fundamental Analysis

NASDAQ:CADL - Nasdaq - US1374041093 - Common Stock - Currency: USD

5.91  +0.21 (+3.68%)

Premarket: 5.95 +0.04 (+0.68%)

Fundamental Rating

1

Overall CADL gets a fundamental rating of 1 out of 10. We evaluated CADL against 561 industry peers in the Biotechnology industry. CADL may be in some trouble as it scores bad on both profitability and health. CADL has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CADL has reported negative net income.
In the past year CADL has reported a negative cash flow from operations.
CADL had negative earnings in each of the past 5 years.
CADL had a negative operating cash flow in each of the past 5 years.
CADL Yearly Net Income VS EBIT VS OCF VS FCFCADL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -51.63%, CADL is in line with its industry, outperforming 45.28% of the companies in the same industry.
CADL has a Return On Equity (-83.19%) which is in line with its industry peers.
Industry RankSector Rank
ROA -51.63%
ROE -83.19%
ROIC N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
CADL Yearly ROA, ROE, ROICCADL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CADL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CADL Yearly Profit, Operating, Gross MarginsCADL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for CADL has been increased compared to 1 year ago.
CADL has more shares outstanding than it did 5 years ago.
CADL has a better debt/assets ratio than last year.
CADL Yearly Shares OutstandingCADL Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CADL Yearly Total Debt VS Total AssetsCADL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

CADL has an Altman-Z score of 1.51. This is a bad value and indicates that CADL is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.51, CADL is in the better half of the industry, outperforming 70.94% of the companies in the same industry.
A Debt/Equity ratio of 0.04 indicates that CADL is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.04, CADL is doing worse than 61.14% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 1.51
ROIC/WACCN/A
WACCN/A
CADL Yearly LT Debt VS Equity VS FCFCADL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CADL has a Current Ratio of 2.77. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.77, CADL is not doing good in the industry: 67.91% of the companies in the same industry are doing better.
CADL has a Quick Ratio of 2.77. This indicates that CADL is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.77, CADL is not doing good in the industry: 66.31% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.77
CADL Yearly Current Assets VS Current LiabilitesCADL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CADL have decreased strongly by -21.43% in the last year.
CADL shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CADL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.76% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-2.69%
EPS Next 2Y2.79%
EPS Next 3Y-2.78%
EPS Next 5Y22.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CADL Yearly Revenue VS EstimatesCADL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2027 2028 2029 2030 500M 1B
CADL Yearly EPS VS EstimatesCADL Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CADL. In the last year negative earnings were reported.
Also next year CADL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CADL Price Earnings VS Forward Price EarningsCADL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CADL Per share dataCADL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as CADL's earnings are expected to decrease with -2.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.79%
EPS Next 3Y-2.78%

More info and screens

0

5. Dividend

5.1 Amount

CADL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANDEL THERAPEUTICS INC

NASDAQ:CADL (5/20/2025, 8:00:01 PM)

Premarket: 5.95 +0.04 (+0.68%)

5.91

+0.21 (+3.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)N/A N/A
Inst Owners51.6%
Inst Owner Change28.92%
Ins Owners18.61%
Ins Owner Change-35.17%
Market Cap291.19M
Analysts86
Price Target21.42 (262.44%)
Short Float %13.3%
Short Ratio5.52
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)10.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-20%
EPS NY rev (1m)9.37%
EPS NY rev (3m)-31.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.39
P/tB 4.39
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-1.28
Fwd EYN/A
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0
BVpS1.35
TBVpS1.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.63%
ROE -83.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.97%
ROA(5y)-50.92%
ROE(3y)-140.08%
ROE(5y)-109.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.77
Altman-Z 1.51
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)71.98%
Cap/Depr(5y)525.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-2.69%
EPS Next 2Y2.79%
EPS Next 3Y-2.78%
EPS Next 5Y22.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.06%
EBIT Next 3Y11.37%
EBIT Next 5Y83.58%
FCF growth 1Y22.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.09%
OCF growth 3YN/A
OCF growth 5YN/A